Rare diseases
Investigational molecules
Locations
290 conditions with trials, the busiest first
1 641 trials across Europe, recruiting first
Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
FranceObinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial
FranceDurable HIV-1 control with 10-1074-LS, 3BNC117-LS and nivolumab in adults on ART: a randomized double‑blind placebo‑controlled trial
DenmarkEfficacy of subcutaneous modified dust mite allergen extract in adults and children with allergic rhinitis/rhinoconjunctivitis due to house dust mites
SpainMethotrexate tapering versus usual care in elderly (≥70) patients with rheumatoid arthritis in low disease activity – drug combination study
DenmarkSafety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study
FranceStandardization of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts and histamine dihydrochloride in skin testing for patients with dust mite allergy
SpainSafety and Efficacy Study of FOXP3‑T4 and Aldesleukin in Patients with IPEX Syndrome
FranceMaintenance versus tapered TNF‑alpha inhibitor therapy (golimumab, etanercept, adalimumab) in children and adolescents with juvenile idiopathic arthritis
NorwayStudy of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis
BelgiumSafety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission
FranceLong‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis
AustriaThe therapies tested most often in Immune system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
